### Prostate cancer: Improved characterisation of patients and disease

**Poster Session 78**

**Monday 19 March**

**14:00 - 15:30**

**Location:** Blue Area, Room 1 (Level 0)

**Chairs:** S. Boxler, Bern (CH)  
W.C. Loidl, Linz (AT)  
S.V. Yrastorza, Quezon (PH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1058</td>
<td>Verification for staging groups of the American joint committee on prostate cancer: Emphasis on the Gleason score</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, Federico II University, Dept. of Urology, Naples, Italy, San Raffaele Turro Hospital, Dept. of Urology, Milan, Italy |
Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, Netherlands, The, Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, Netherlands, The, Radboud University Medical Center, Radboud Institute for Health Sciences, Dept. of Urology, Nijmegen, Netherlands, The, Academic Medical Center, Dept. of Radiotherapy, Amsterdam, Netherlands, The, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiotherapy, Amsterdam, Netherlands, The, VU University Medical Center, Dept. of Urology, Amsterdam, Netherlands, The, Elisabeth-TweeSteden Hospital, Dept. of Urology, Tilburg, Netherlands, The, Radboud University Medical Center, Radboud Institute for Health Sciences, Dept. of Pathology, Nijmegen, Netherlands, The, Radboud University Medical Center, Radboud Institute for Health Sciences, Department for Health Evidence, Nijmegen, Netherlands, The |
1061  Withdrawn
To be confirmed

1062  Do the Prostate Imaging Reporting and Data System scores reflect oncological outcome? Potential usefulness of scoring criteria-based assessment
By: Uehara S.1, Matsuoka Y.1, Tanaka H.2, Yasuda Y.1, Kijima T.1, Yoshida S.1, Yokoyama M.1, Ishioka J.1, Saito K.1, Kihara K.1, Fujii Y.1
1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

1063  The number of positive mpMRI-targeted cores is linearly associated with the risk of multi-focal clinically significant prostate cancer: Implications for correct patient staging and counselling
By: Stabile A.1, Dell’Oglio P.1, Zaffuto E.1, Gandaglia G.1, Capitanio U.1, Fossati N.1, Maga T.1, Soligo M.2, Brembilla G.3, Brunelli L.3, Damiano R.4, Shariat S.5, Esposito A.3, De Cobelli F.3, Montorsi F.1, Karnes R.J.2, Briganti A.1
1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy, 4Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria

1064  Assessing the risk of upstaging using the International Society of Urological Pathology 2014 classification in patients with prostate cancer treated with robotic radical prostatectomy: A novel nomogram
1Sant’ Andrea Hospital, Sapienza University of Rome, Dept. of Urology, Rome, Italy, 2ICOT Hospital of Latina, Sapienza University, Dept. of Urology, Latina, Italy, 3St Antonius Hospital Gronau, Dept. of Urology, Pediatric Urology and Urological Oncology, Gronau, Germany, 4Istituto Nazionale Tumori Regina Elena, Dept. of Urology, Rome, Italy

1065  Prostatic nerve subtype predicts post-prostatectomy recurrence
By: Reeves F.1, Battye S.2, Roth H.3, Peters J.S.1, Hovens C.1, Costello A.J.1, Corcoran N.M.1
1Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, 2TissuPath, Dept. of Pathology, Mount Waverley, Australia, 3Peninsula Health, Dept. of Urology, Frankston, Australia

1066  How does the length of extra-capsular prostatic extension is a predictor factor of biochemical recurrence in pT3a R0 N0 M0 stage?
By: Montesi L.1, Galosi A.1, Leone L.1, Milanese G.1, Dell’Atti L.1, Palagonia E.1, Montironi R.2
1University Hospital Ospedali Riuniti, Dept. of Urology, Ancona, Italy, 2University Hospital Ospedali Riuniti, Dept. of Pathological Anatomy, Ancona, Italy
Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration


1 Laval University, Dept. of Urology, Québec, Canada, 2 Laval University, Dept. of Nuclear Medicine, Québec, Canada

The evolution of prostate cancer care in a tertiary referral hospital over the past decade


1 University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 2 University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium

Ethnicity and prostate cancer: Implications for improving outcomes

By: Pathmanathan B., Batura D., Mukerji G., Mohamed O., Hellawell G.

1 Imperial College Healthcare NHS Trust, Clinical Research Department, London, United Kingdom, 2 London North West Healthcare NHS Trust, Dept. of Urology, London, United Kingdom

Contemporary national trends in localized prostate cancer risk profile at diagnosis


1 Brigham and Women’s Hospital, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, 2 Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, 3 University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4 Henry Ford Health System, Vatikutti Urology Institute, Detroit, United States of America, 5 Brigham And Women’s Hospital, Harvard Medical School, Division of Urological Surgery, Boston, United States of America

Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: A contemporary population-based update in light of the 2012 USPSTF recommendations


1 University of Montreal, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 2 Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, 3 Elbe Klinikum Stade, Dept. of Urology, Stade, Germany, 4 University Medical Center Hamburg-Eppendorf, Dept. of
Urology, Hamburg, Germany, \textsuperscript{5}Prostate Cancer Center Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany